Advertisement

Guidelines for Neuroleptic Relapse Prevention in Schizophrenia: Towards a Consensus View

  • W. Kissling
  • J. M. Kane
  • T. R. E. Barnes
  • S. J. Dencker
  • W. W. Fleischhacker
  • M. J. Goldstein
  • D. A. W. Johnson
  • S. R. Marder
  • F. Müller-Spahn
  • J. Tegeler
  • B. Wistedt
  • B. Woggon

Abstract

With the introduction of neuroleptics almost 40 years ago medication became available that had demonstrable efficacy in the prevention of relapse in stabilized schizophrenic patients (Davis 1980; Kane and Lieberman 1987). Nevertheless, the course of schizophrenia still remains unsatisfactory for a large proportion of patients, with relapse rates of 50% during the year following their last episode. Only 16% remain free of relapse for a period of 5 years (Gaebel and Pietzcker 1985; Gmür and Tschopp 1988; Shepherd et al. 1989).

Keywords

Relapse Rate Schizophrenic Patient Maintenance Treatment Tardive Dyskinesia Relapse Prevention 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45:79–80PubMedCrossRefGoogle Scholar
  2. Barnes TRE (1990) Comment on the WHO consensus statement. Br J Psychiatry 156:413–414PubMedCrossRefGoogle Scholar
  3. Chien CP (1975) Drugs and rehabilitation in schizophrenia. In: Greenblatt M (eds) Drugs in combination with other therapies. Grune and Stratton, New York, pp 13–34Google Scholar
  4. Crow TJ, McMillan JF, Johnson AL, Johnstone EC (1986) The Northwick Park study of first episodes of schizophrenia: II. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 148:120–127PubMedCrossRefGoogle Scholar
  5. Davis JM (1980) Antipsychotic drugs. In: Kaplan HI, Freedman AM, Sadock BJ (ed) Comprehensive textbook of psychiatry, 3rd edn. Williams and Wilkins, BaltimoreGoogle Scholar
  6. Davis J (1988) Maintenance medication. In: Barnes TRE (ed) Depot neuroleptics: a consensus. London: Mediscript, pp 47–52Google Scholar
  7. Forsman A, Eklund K (1991) Minimal effective dose and relapse: double-blind trial: Haldol decanoas versus placebo. Clin Neuropharmacol (in press)Google Scholar
  8. Gaebel W, Pietzcker A (1985) One-year-outcome of schizophrenic patients — the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry 18:235–239PubMedCrossRefGoogle Scholar
  9. Gerlach J, Casey DE (1988) Tardive dyskinesia. Acta Psychiatr Scand 77:369–378PubMedCrossRefGoogle Scholar
  10. Gmür M, Tschopp A (1988) Die Behandlungskontinuität bei schizophrenen Patienten in der Ambulanz. Eine Fünfjahres-Nachuntersuchung. Nervenarzt 59:727–730PubMedGoogle Scholar
  11. Goldstein MJ, Rodnick EH, Evans JR, May PRA, Steinberg M (1978) Drug and family therapy in the aftercare and treatment of acute schizophrenia. Arch Gen Psychiatry 35:1169–1177PubMedCrossRefGoogle Scholar
  12. Hogarty GE, Goldberg SC, Collaborative Study Group (1974) Drug and sociotherapy in the aftercare of schizophrenic patients: one year relapse rates. Arch Gen Psychiatry 28:54–64CrossRefGoogle Scholar
  13. Hogarty GE, Ulrich RF, Mussare F, Aristigueta N (1976) Drug discontinuation among long-term successfully maintained schizophrenic outpatients. Dis Nerv Syst 37:494–500PubMedGoogle Scholar
  14. Hogarty GE, McEvoy JP, Munet M, DiBarry AL, Bartone P, Cather R, Cooley SJ, Ulrich RF, Carter M, Madonia MU (1988) Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Arch Gen Psychiatry 45:797–805PubMedCrossRefGoogle Scholar
  15. Johnson DAW (1984) Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 5, Sec 2:13–21Google Scholar
  16. Johnson DAW, Ludlow JM, Street K, Taylor RDW (1987) Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilized out-patients with schizophrenia. Br J Psychiatry 151:634–638PubMedCrossRefGoogle Scholar
  17. Kane JM (1985) Compliance issues in outpatient treatment. J Clin Psychopharmacol 5:225–275CrossRefGoogle Scholar
  18. Kane JM (1987) Treatment of schizophrenia. Schizophrenia Bull 13, 1Google Scholar
  19. Kane JM, Rifkin A, Quitkin F, Naya D, Ramos-Lorenzi J (1982) Fluphenazine versus placebo in patients with remitted acute first episode schizophrenia. Arch Gen Psychiatry 39:70–73PubMedCrossRefGoogle Scholar
  20. Kane JM, Rifkin A, Woerner M et al. (1983) Low dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry 40:893–896PubMedCrossRefGoogle Scholar
  21. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22:254–258PubMedGoogle Scholar
  22. Kane JM, Lieberman JA (1987) Maintenance pharmacotherapy in schizophrenia. In: Meltzer HE (ed) Psychopharmacology: the third generation of progress. Raven, New YorkGoogle Scholar
  23. Kissling W (1988) Consensus regarding indication for prophylactic neuroleptic treatment -necessary, but unattainable? In: Barnes TRE (ed) Depot neuroleptics — a consensus. Antwerp, 19 Nov 87. Mediscript, Lond, pp 41–46Google Scholar
  24. Leff JP, Wing JK (1971) Trial of maintenance therapy in schizophrenia. Br Med J 3:559–604CrossRefGoogle Scholar
  25. Marder SR, van Putten R, Mintz J, Lebell M, McKenzie J, Galtico G (1984) Maintenance therapy: New findings. In: Kane JM (ed) Drug maintenance strategies in schizophrenia. APA, WashingtonGoogle Scholar
  26. Marder SR, van Putten R, Mintz J, Lebell M, McKenzie J, May RPA (1987) Low and conventional-dose maintenance therapy with fluphenazine decanoate. Arch Psychiatry 44:518–522CrossRefGoogle Scholar
  27. Marsden CD (1985) Is tardive dyskinesia a unique disorder? In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia — research and treatment. Springer, Berlin Heidelberg New YorkGoogle Scholar
  28. Möller HJ, von Zerssen D (1981) Depressive Symptomatik im stationären Behandlungsverlauf von 280 schizophrenen Patienten. Pharmacopsychiatry 14:172–179CrossRefGoogle Scholar
  29. Möller HJ, Kissling W, Stoll KD, Wendt G (1989) Psychopharmakotherapie. Ein Leitfaden für Klinik und Praxis. Kohlhammer, StuttgartGoogle Scholar
  30. Müller P (ed) (1982) Zur Rezidivprophylaxe schizophrener Psychosen. Enke, StuttgartGoogle Scholar
  31. Rifkin A, Quitkin F, Klein DF (1975) Akinesia: a poorly recognized drug induced extrapyramidal behavioral disorder. Arch Gen Psychiatry 32:672–674CrossRefGoogle Scholar
  32. Rifkin A, Quitkin F, Rabiner CJ, Klein DF (1977) Fluphenazine decanoate, oral fluphenazine and placebo in the treatment of remitted schizophrenics: I. Relapse rates after one year. Arch Gen Psychiatry 34:43–47PubMedCrossRefGoogle Scholar
  33. Schooler NR, Keith S J (1990) Role of medication in psychosocial treatment. In: Herz MI, Keith SJ, Docherty JP (eds) Handbook of schizophrenia, vol. 4: Psychosocial treatment of schizophrenia. Elsevier, AmsterdamGoogle Scholar
  34. Shepherd M, Watt D, Falloon I, Smeeton N (1989) The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychological Medicine, Monograph Suppl. 15. Cambridge University Press, CambridgeGoogle Scholar
  35. Siris SG, Morgón V, Fagerstrom R, Rifkin A, Cooper TB (1987) Adjunctive imipramine in the treatment of post-psychotic depression: a controlled trial. Arch Gen Psychiatry 44:533–539PubMedCrossRefGoogle Scholar
  36. Troshinsky CH, Aaronson HG, Stone RK (1962) Maintenance phenothiazine in the aftercare of schizophrenic patients. Pa Psychiatr Q 2:11–15Google Scholar
  37. Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31:67–72PubMedCrossRefGoogle Scholar
  38. Wistedt B (1981) A depot neuroleptic withdrawal study: a controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatr Scand 64:65–84PubMedCrossRefGoogle Scholar
  39. World Health Organization Heads of Centres Collaborating in WHO Co-Ordinated Studies on Biological Aspects of Mental Illness (1990) Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. Br J Psychiatry 156:412CrossRefGoogle Scholar
  40. Youssef HA, Waddington J (1987) Morbidity and mortality in tardive dyskinesia: associations with chronic schizophrenia. Acta Psychiatr Scand 75:74–77PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • W. Kissling
  • J. M. Kane
  • T. R. E. Barnes
  • S. J. Dencker
  • W. W. Fleischhacker
  • M. J. Goldstein
  • D. A. W. Johnson
  • S. R. Marder
  • F. Müller-Spahn
  • J. Tegeler
  • B. Wistedt
  • B. Woggon

There are no affiliations available

Personalised recommendations